3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Interventions
Dexamethasone
116
Bortezomib
63
Cyclophosphamide
51
Lenalidomide
49
Calcium Dobesilate
46
Melphalan
37
pomalidomide
36
fludarabine
28
Filgrastim
26
fludarabine phosphate
23
carfilzomib
22
daratumumab
21
Whole-Body Irradiation
17
Granulocyte Colony-Stimulating Factor
17
Mycophenolic Acid
15
Antilymphocyte Serum
15
dexamethasone acetate
14
Tacrolimus
14
Thalidomide
13
Cyclosporine
13
Busulfan
13
Radiotherapy
12
Peripheral Blood Stem Cell Transplantation
12
ixazomib
11
dexamethasone 21-phosphate
10
auricularum
10
pembrolizumab
9
Stem Cell Transplantation
9
Rituximab
9
Etoposide
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
angiotensin I (1-7)
×
Plasma cell
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled